News & Updates
Filter by Specialty:
Pembrolizumab extends RFS in stage II melanoma
Pembrolizumab extended recurrence-free survival (RFS) in patients with high-risk stage II melanoma who had undergone complete resection, interim analysis results of the phase III KEYNOTE-716 trial showed.
Pembrolizumab extends RFS in stage II melanoma
01 Nov 2021
Poor metabolic health may lead to subsequent gastrointestinal cancers
Individuals with long-term metabolic syndrome are at increased risk of developing gastrointestinal cancer overall, including colorectal and pancreatic cancers and hepatocellular carcinoma, with the risk increase independent of genetic predisposition, a study has found.
Poor metabolic health may lead to subsequent gastrointestinal cancers
31 Oct 2021
Local failure common in metastases from right-sided primary CRC treated with SABR
Local failure (LF) is more likely to occur in colorectal cancer (CRC) metastases treated with stereotactic ablative radiotherapy (SABR) if originating from right-sided primary CRC compared with left-sided, a study has found. In addition, LF rates are highest with liver metastases than other metastatic sites.
Local failure common in metastases from right-sided primary CRC treated with SABR
31 Oct 2021
Patients presenting with advanced-stage pancreatic cancer reveal cracks in imaging-based surveillance
High-risk individuals who develop neoplastic progression to pancreatic cancer or high-grade dysplasia can present at an advanced stage despite showing no lesions during prior imaging surveillance evaluations, a new study has found.
Patients presenting with advanced-stage pancreatic cancer reveal cracks in imaging-based surveillance
31 Oct 2021
Dietary ALA intake may lower risks of all-cause, CVD, CHD mortality
Dietary intake of alpha linolenic acid (ALA) appears to reduce the risk of mortality from all causes, cardiovascular disease (CVD), and coronary heart disease (CHD) but may slightly increase the risk of cancer mortality, according to a systematic review and meta-analysis. Moreover, an association exists between higher blood levels of ALA and a lower risk of all-cause and CHD mortality.